Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Precancerous Conditions 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Cardiotoxicity 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × Fluorophotometry × Clear all
NCT00436566 2022-08-05

Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery

Mayo Clinic

Phase 2 Completed
122 enrolled 22 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡